Latest Financial Performance News

Civmec’s 1H FY25 results reveal robust revenue growth and a strong balance sheet, underpinned by a diversified project pipeline and strategic moves into naval shipbuilding and material handling equipment manufacturing.

Civmec Limited reports solid first-half FY25 results with revenue growth and a stable dividend, while navigating margin pressures and advancing strategic projects.

HealthCo Healthcare & Wellness REIT reported a solid 5% increase in Funds From Operations (FFO) and Distribution Per Unit (DPU) for the first half of FY25, underpinned by stable asset valuations and a robust healthcare portfolio.

HealthCo Healthcare & Wellness REIT reports solid 5% growth in FFO and DPU for 1H FY25, maintaining strong occupancy and gearing levels despite ongoing Healthscope lease speculation.

Cochlear Limited has reported a robust half-year performance with a 7% increase in underlying net profit and an 8% rise in interim dividends, driven by strong sales in cochlear and acoustic implants despite a decline in services revenue.

HealthCo Healthcare and Wellness REIT reported a sharp increase in half-year losses to $15.4 million, alongside a portfolio reduction and steady funds from operations, highlighting a complex transition phase.

Unibail-Rodamco-Westfield delivered robust FY-2024 results with a 7% rise in like-for-like EBITDA and adjusted recurring EPS surpassing guidance, supported by strong retail and convention business performance. The company also announced a 40% increase in its proposed dividend, reflecting confidence in its financial health and strategic asset management.

Ten Sixty Four Limited has successfully exited external administration following the full effectuation of its Deed of Company Arrangement, marking a pivotal step toward resuming normal operations and ASX trading.

Hancock & Gore Limited (ASX: HNG) showcased a transformative year at its 121st AGM, spotlighting a strategic merger with Schoolblazer that creates a leading global uniforms platform and signals a new phase of growth and portfolio simplification.

Pro Medicus has delivered a record first half in FY25, driven by strong revenue growth, major contract wins, and successful implementations that position it well for future expansion.

Pro Medicus Limited has delivered a record interim profit of $51.7 million, boosted by major North American contract wins and strong margin expansion.

Pro Medicus Limited delivered a robust half-year performance ending December 2024, with after-tax profits soaring 42.7% to $51.74 million and revenues climbing 31.1% to $97.2 million, driven by significant contract wins in North America and sustained growth in Australia.